Novartis' Exelon Patent Is Invalid, UK Appeals Court Says
A U.K. appeals court on Wednesday affirmed a lower court's ruling invalidating a Novartis AG patent covering the company's Alzheimer's drug Exelon in a lawsuit brought by a subsidiary of generic-drug...To view the full article, register now.
Already a subscriber? Click here to view full article